ArticlePharmaceutical biology2026
Jianpi Zishen Decoction ameliorates renal damage induced by systemic lupus erythematosus through inhibition of the TLR4/MAPK pathway.
Article in Pharmaceutical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextSystemic lupus erythematosus (SLE) is an autoimmune disease involving multiple systems. Jianpi Zishen Decoction (JZD) is a TCM formula used to improve proteinuria in SLE, which has been widely used in the treatment of renal damage in SLE.
objectiveTo investigate the potential targets and action mechanisms of JZD in ameliorating renal damage in SLE through network pharmacology and
methodsThe main components of JZD were determined using UPLC-Q-TOF-MS/MS. The potential targets and action mechanisms of JZD were explored using network pharmacology and molecular docking techniques. MRL/lpr mice were used as animal models, and their renal pathological changes were observed by HE staining, periodic acid-Schiff staining, and Masson staining. Additionally, mouse glomerular ultrastructure was observed using TEM. The level of urinary protein, immunoinflammatory indicators, and TLR4/MAPK pathway-related molecules were detected through a variety of experimental methods. Furthermore, the effects of JZD on LPS-stimulated HMCs were evaluated.
resultsA total of 27 prototype components were identified in the blood-entered component of JZD. Animal experiments showed that JZD effectively ameliorated renal damage and immune disorders, reduced glomerular scores and vascular wall scores, as well as attenuated IgG and C3 deposition in the kidneys of MRL/lpr mice. Network pharmacological analysis and molecular docking identified TLR4 as a core potential target of JZD's efficacy. JZD inhibited the expression of TLR4, p38, JNK, AP-1, and pro-inflammatory factors in the kidneys of MRL/lpr mice.
conclusionJZD could ameliorate SLE renal damage and its active ingredients exerted therapeutic effects by inhibiting the TLR4/MAPK pathway, highlighting the therapeutic potential of JZD in modulating immunoinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.